Theriva Biologics (NYSEAMERICAN:TOVX) Trading 8.4% Higher – Here’s What Happened

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) shares traded up 8.4% during mid-day trading on Monday . The stock traded as high as $0.2801 and last traded at $0.21. 256,426,773 shares were traded during trading, an increase of 7,594% from the average session volume of 3,332,882 shares. The stock had previously closed at $0.1937.

Theriva Biologics Stock Up 8.4%

The company has a market cap of $7.09 million, a P/E ratio of -0.01 and a beta of 0.53. The stock has a 50-day moving average of $0.19 and a 200 day moving average of $0.27. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.74 and a quick ratio of 1.74.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings data on Thursday, March 12th. The company reported $1.30 earnings per share for the quarter.

Institutional Trading of Theriva Biologics

A hedge fund recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC increased its position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 212,087 shares of the company’s stock after acquiring an additional 183,878 shares during the period. Geode Capital Management LLC owned about 0.63% of Theriva Biologics worth $45,000 as of its most recent filing with the Securities and Exchange Commission. 6.17% of the stock is currently owned by institutional investors and hedge funds.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.